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Abstract Annexin A9 is a novel member of the annexin family
of Ca2+ and phospholipid binding proteins which has so far only
been identi¢ed in EST data bases and whose deduced protein
sequence shows mutations in residues considered crucial for
Ca2+ coordination in other annexins. To elucidate whether the
annexin A9 protein is expressed as such and to characterize its
biochemical properties we probed cell extracts with speci¢c anti-
annexin A9 antibodies and developed a recombinant expression
system. We show that the protein is found in HepG2 hepatoma
cell lysates and that a green £uorescent protein-tagged form is
abundantly expressed in the cytosol of HeLa cells. Recombinant
expression in bacteria yields a soluble protein that can be en-
riched by conventional chromatographic procedures. The protein
is capable of binding phosphatidylserine containing liposomes
albeit only at Ca2+ concentrations exceeding 2 mM. Moreover
and in contrast to other annexins this binding appears to be
irreversible as the liposome-bound annexin A9 cannot be re-
leased by Ca2+ chelation. These results indicate that annexin
A9 is a unique member of the annexin family whose intracellular
activity is not subject to Ca2+ regulation.
, 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Annexins are a family of evolutionarily conserved proteins
characterized by their ability to interact with membrane phos-
pholipids in a Ca2þ-dependent manner. This property most
likely underlies annexin functions in membrane organization
and tra⁄c and has been proposed to depend on so-called type
II Ca2þ binding sites found in annexin proteins (for recent
reviews on annexins see [1,2]). Type II sites are located in
the protein core domains which are structurally conserved
within the annexin family and are built of four or eight ho-
mologous segments known as annexin repeats. The repeats
form a compact and slightly curved disc with the type II
Ca2þ sites protruding at the convex side of the disc (for re-
views on annexin structure see [3^5]). Typically, these type II
sites are formed by an interhelical loop and an acidic amino
acid, called cap residue, with the latter residing approximately
40 residues C-terminal to the loop and providing carboxyl
oxygens for Ca2þ coordination in the folded molecule [6]. In
membrane-bound annexins Ca2þ bound in the type II sites
serves a bridging function to the phospholipid headgroups
by coordinating not only to carbonyl and carboxyl oxygens
of the protein but also to the phosphoryl moiety of membrane
phospholipids [7]. Amino acids participating in the formation
of type II binding sites are all found in an individual annexin
repeat and a typical four repeat annexin core should thus
contain four type II sites. While this has been proven correct
for annexin A5, albeit only at higher Ca2þ concentrations [8],
two annexins, A1 and A2, have su¡ered amino acid substitu-
tions of the cap residue in the ¢rst annexin repeat. In both
cases the elimination of the acidic residue at the cap position
most likely renders the respective site incapable of binding
Ca2þ as revealed by structural analyses of Ca2þ-loaded annex-
in crystals [9,10].
All annexins structurally or biochemically characterized to
date contain at least three of the type II Ca2þ sites and it is
Ca2þ binding to these sites that enables the proteins to dock
peripherally onto the cytoplasmic lea£ets of cellular mem-
branes [11,12]. As this property has been considered a hall-
mark of the annexin family it was highly unexpected that an
annexin sequence lacking the acidic cap residue in all four
annexin repeats was identi¢ed by Morgan and Fernandez in
a data base search of human expressed sequence tags (ESTs)
[13]. This annexin, initially termed annexin 31 and with the
new annexin terminology in place now known as annexin A9,
has its closest relative in annexin A2, a protein thought to
function in the organization and regulation of membrane/cy-
toskeleton linkages [14]. While this classi¢cation is based on
sequences of the annexin core region similar sequence features
are also found in the N-terminal domains of annexins A2 and
A9. Typically, the N-terminal domains of di¡erent annexins
are highly divergent and are believed to confer speci¢city to
individual members of the family (for review see [2]).
Although showing limited sequence identity, the N-terminal
regions of annexins A2 and A9 share the potential of forming
an amphipathic K-helix. In annexin A2 this helix formation
has been experimentally veri¢ed with the hydrophobic side of
the helix representing the binding surface for a speci¢c intra-
cellular protein ligand, S100A10 [15,16].
Given the unique sequence features displayed by annexin
A9 we sought to determine whether the protein is expressed in
cultured cells and whether it shows unique biochemical char-
acteristics. By employing annexin A9-speci¢c antibodies we
detect low-level protein expression in HepG2 but not HeLa
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cells. Moreover we show that the annexin A9 protein ex-
pressed in bacteria is capable of interacting with phospholipid
liposomes in a Ca2þ-dependent manner. However, the inter-
action requires Ca2þ concentrations in the millimolar range
and occurs in an irreversible manner. This argues against a
participation of Ca2þ in regulating annexin A9 function with-
in cells and supports the view that the protein ful¢lls highly
speci¢c functions not displayed by other members of the fam-
ily.
2. Materials and methods
2.1. Cell culture and preparation of cell lysates
HeLa cells were maintained in Dulbecco’s modi¢ed Eagle’s medium
(BioWhittaker Europe, Verviers, Belgium) with 10% fetal calf serum,
glutamine and antibiotics in a 7% CO2 incubator at 37‡C. HepG2
cells were maintained in RPMI 1640 medium (BioWhittaker Europe)
supplemented with 10% fetal calf serum, glutamine and antibiotics in
a 5% CO2 incubator at 37‡C.
Cells grown to 70^80% con£uence were harvested, resuspended in
lysis bu¡er (20 mM HEPES, pH 7.4, 0.1% sodium dodecyl sulfate
(SDS), 0.5% Triton X-100, 150 mM NaCl, 1 mM EDTA, 1 mM
phenylmethylsulfonyl £uoride (PMSF)) and incubated for 30 min at
4‡C. Cell lysates were then centrifuged at 10 000Ug for 10 min at 4‡C
to pellet cellular debris. Supernatants were resolved on a 12% SDS^
polyacrylamide gel electrophoresis (PAGE) gel and transferred to a
polyvinylidene di£uoride(PVDF) membrane. Blots were blocked with
5% milk powder in TBS-T (20 mM Tris^HCl, pH 7.4, 150 mM NaCl,
0.2% Tween 20) prior to probing with immunoa⁄nity-puri¢ed anti-
annexin A9 antibodies.
2.2. Cloning of green £uorescent protein (GFP) expression constructs
Annexin A1^GFP and annexin A2^GFP constructs have been de-
scribed previously [11]. To obtain annexin A9^GFP, with enhanced
GFP fused to the carboxy-terminus of protein, full-length annexin A9
cDNA was ampli¢ed by polymerase chain reaction (PCR) (forward
primer with 5P-£anking EcoRI site 5P-accatgtctgtgactggcgggaag-3P, re-
verse primer with a SalI site replacing the stop codon 5P-catgtctt-
cagccctgcacaaggc-3P) using the bacterial expression vector pET-
23a(+)mod:/anxA9 (see below) as template. The PCR fragment was
inserted into the linearized mammalian expression vector pEGFP-
N3 (Clontech, Heidelberg, Germany) and correctness veri¢ed by se-
quence analysis.
2.3. Transfections and £uorescence microscopy
Transient transfections employed HeLa cells grown on coverslips
which were transfected using E¡ectene (Qiagen, Hilden, Germany).
Twenty-four hours after transfection, cells were ¢xed with 4% form-
aldehyde in phosphate-bu¡ered saline for 10 min at room tempera-
ture. Localization of the respective annexin was visualized by GFP
£uorescence using a DM RXA £uorescence microscope (Leica, Wetz-
lar, Germany).
2.4. Expression of annexin A9 in a coupled transcription^translation
reticulocyte lysate system
Full-length annexin A9 was expressed in a coupled in vitro tran-
scription^translation system using a vector containing the complete
cDNA of annexin A9 under T7 promoter control and the TNT^T7
reticulocyte lysate system in the presence of methionine essentially as
described by the supplier (Promega, Madison, WI, USA). 1 mM me-
thionine and 1 Wg plasmid DNA were used in one 50 Wl assay. As a
negative control an assay was performed with the empty vector. Re-
actions were incubated at 30‡C for 90 min.
2.5. Reverse transcription and PCR (RT-PCR)
Total RNA was isolated using the Qiagen RNeasy kit according to
the manufacturer’s protocol with the Qiashredder columns for cell
lysis. Total RNA (5 Wg) was subjected to reverse transcription using
the SuperScript II RNase H3 Reverse Transcriptase (Invitrogen Life
Technologies, Carlsbad, CA, USA) and reaction conditions speci¢ed
by the manufacturer. Reactions were primed with 100 pM random
hexamers. The PCR reaction was heated for 2 min at 94‡C and started
in a 25 Wl volume using 5 Wl of the cDNA mix as a template (primers
see below), followed by 35 cycles of denaturing at 94‡C for 45 s,
annealing at 56‡C for 1 min and extension at 72‡C for 1 min. In
the ¢nal cycle, extension time was increased to 7 min.
2.6. Generation and immunoa⁄nity puri¢cation of anti-annexin
A9 antibodies
Rabbit polyclonal antiserum to a synthetic peptide corresponding
to amino acids 8^29 of human annexin A9 was obtained by standard
immunization procedures (Eurogentec, Seraing, Belgium). For a⁄nity
puri¢cation, column fractions enriched in bacterially expressed annex-
in A9 were separated by SDS^PAGE and transferred onto PVDF
membrane by Western blotting. Immobilized proteins were visualized
by Ponceau staining and the membrane strip carrying the immobilized
annexin A9 was cut out. Serum samples were diluted with TBS-T
containing 5% non-fat milk powder and incubated for 2 h with the
membrane strip, then washed three times with TBS-T. Adsorbed anti-
annexin A9 antibodies were eluted by placing the membrane strip in
100 mM glycine pH 2.7. Eluted antibodies were immediately neutral-
ized with 1/10 volume 1 M Tris and 10UTBS-T. Concentration of the
a⁄nity-puri¢ed antibodies employed Microcon YM-30 centrifugation
¢lter devices (30 MWCO, Millipore, Bedford, MA, USA).
2.7. Expression and puri¢cation of human annexin A9
The complete cDNA encoding human annexin A9 was ampli¢ed
from a human fetal liver MATCHMAKER cDNA library (BD Clon-
tech, Heidelberg, Germany) by PCR using the following primers, each
with 5P-£anking EcoRI sites: 5P-atgtctgtgactggcgggaag-3P (forward)
and 5P-tcacatgtcttcagccctg-3P (reverse). The puri¢ed PCR product
was digested with EcoRI and cloned into the bacterial expression
vector pET-23a(+) (Novagen, Heidelberg, Germany) modi¢ed to al-
low expression of full-length annexin A9 without a T7 tag [17]. Cor-
rect insertion of the cDNA was con¢rmed by sequencing.
Escherichia coli expression strain BL21(DE3)pLysS (Stratagene,
Amsterdam, The Netherlands) was transformed with the pET-
23a(+)mod:/anxA9 expression vector. Transformed bacteria were
grown at 37‡C in LB medium containing 150 Wg/ml ampicillin until
the OD600 reached 0.6. Expression of annexin A9 was induced with
1 mM isopropyl-L-D-thiogalactose (IPTG) for 3 h at 37‡C and the
bacteria were then harvested by centrifugation. The cell pellet was
resuspended in 1/10 culture volume of bu¡er L (50 mM Tris^HCl,
pH 7.5, 150 mM NaCl, 1 mM dithiothreitol (DTT), 1 mM EGTA,
0.5 mM PMSF) and lysed by three freeze/thawing cycles and sonica-
tion (3U30 s). Insoluble material was removed by centrifugation at
30 000Ug for 30 min at 4‡C followed by an additional centrifugation
step at 100 000Ug for 40 min at 4‡C. The annexin A9-containing
supernatant was dialyzed against bu¡er D (20 mM imidazole^HCl,
pH 7.5, 10 mM NaCl, 1 mM DTT, 1 mM EGTA, 0.5 mM PMSF).
Annexin A9 was enriched by ion exchange chromatography on DEAE
Sephacel (Amersham Pharmacia Biotech AB, Uppsala, Sweden) using
bu¡er D as column bu¡er. Under these conditions annexin A9 bound
to the column and was eluted using 100 mM NaCl in bu¡er D.
2.8. Phospholipid binding assay
For the phospholipid binding assays, fractions enriched in annexin
A9 were dialyzed against bu¡er D plus 100 mM NaCl but without
EGTA. Binding properties of annexin A9 were assayed in a liposome
pelleting assay [18]. Brie£y, liposomes were generated by sonicating
brain extract (Folch fraction I from bovine brain, Sigma B-1502,
Steinheim, Germany) in water. Binding experiments were performed
in EGTA-free bu¡er D (plus 70 mM NaCl and 2 WM E64) containing
di¡erent CaCl2 concentrations (0.5, 1 and 2.5 mM Ca2þ) or 1 mM
EGTA. Protein fractions in the respective binding bu¡er were ¢rst
centrifuged at 100 000Ug for 15 min at 4‡C to pellet any remaining
insoluble material. Liposomes were then added to a ¢nal concentra-
tion of 2 mg/ml and the reaction mixtures were incubated for 1 h at
room temperature. Liposomes were pelleted by centrifugation at
100 000Ug for 1 h at 4‡C, resuspended in bu¡er D containing
100 mM EGTA or 100 mM EGTA plus 0.2% Triton X-100, to release
Ca2þ-dependently bound annexin A9, and again pelleted by centrifu-
gation. Equivalent amounts of supernatants and pelleted liposomes
were analyzed by SDS^PAGE and subsequent immunoblotting.
2.9. Actin co-sedimentation assay
The ability of annexin A9 to bind or bundle actin was investigated
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as described [19] by co-sedimentation with F-actin in bundling bu¡er
(2 mM Tris^HCl, pH 7.5, 50 mM KCl, 1 mM MgCl2, 0.33 mM ATP,
0.5 mM DTT). Brie£y, 1/50 volume of actin polymerization solution
(2.5 mM KCl, 100 mM MgCl2, 50 mM ATP) was added to 1 mg/ml
rabbit skeletal muscle actin (Cytoskeleton, Denver, CO, USA) in
G-actin bu¡er (5 mM Tris^HCl, pH 8.0, 0.2 mM CaCl2, 0.2 mM
ATP) and the solution was then incubated for 30 min at room temper-
ature. Polymerized F-actin was stored at 4‡C prior to use. In a ¢nal
volume of 200 Wl, 25 Wg F-actin and the fraction enriched in annexin
A9 were incubated for 20 min at room temperature in the presence
(4 mM Ca2þ) or absence (1 mM EGTA) of Ca2þ. The reaction mix-
ture was centrifuged at low speed (15 600Ug, 15 min, 20‡C) to pellet
F-actin bundles, followed by a high speed centrifugation (350 000U g,
15 min, 20‡C) to pellet F-actin. Proteins left in the supernatants were
precipitated with 10% trichloroacetic acid (TCA) and pelleted at
20 000Ug for 15 min at 4‡C. The di¡erent samples were analyzed
by SDS^PAGE and subsequent Western blotting using the polyclonal
anti-annexin A9 antibodies. F-actin was visualized by Coomassie
staining.
2.10. S100A10 overlay assay
S100A10 overlay assays were carried out using protein extracts
from E. coli BL21(DE3)pLysS expressing human annexin A9, a sam-
ple of human annexin A9 enriched by DEAE chromatography (see
above) and heterotetrameric annexin A2^S100A10 complex isolated
from porcine mucosa as positive control [20]. The protein samples
were separated by SDS^PAGE and then transferred onto PVDF
membrane. The membrane was blocked with 2% (w/v) bovine serum
albumin (BSA) in TBS and then washed three times for 10 min with
TBS. Subsequently the membrane was incubated for 1 h at 37‡C with
10 Wg puri¢ed recombinant human S100A10 [21] in 2 ml TBS con-
taining 2% (w/v) BSA and 2 mM DTT. After extensive washing with
TBS, bound S100A10 was detected using a monoclonal anti-S100A10
antibody [22]. To visualize annexin A2 and annexin A9 on the same
blot, the membrane was stripped for 30 min at 50‡C in stripping
bu¡er (67 mM Tris^HCl, pH 6.8, 2% (w/v) SDS and 96 mM L-mer-
captoethanol) and probed using a monoclonal anti-annexin A2 anti-
body [12] or the polyclonal anti-annexin A9 antibody.
3. Results and discussion
3.1. Expression of the annexin A9 protein in cultured cells
Annexin A9 is a very unusual annexin in that all type II
high a⁄nity Ca2þ binding sites characteristic for the annexin
protein family are mutated and therefore predicted to be dys-
functional [13]. Positive selection of an annexin with ablated
type II sites might point towards Ca2þ-independent functions.
Although annexin A9 transcripts have been found in several
human EST libraries [13], the existence of the protein as such
in human cells has not been reported. Therefore, we per-
formed RT-PCR on total RNA from di¡erent cultured cells.
While a number of cells including HeLa did not yield any
speci¢c signal, we could generate a single PCR product of
the expected size in HepG2 cells (Fig. 1A), con¢rming pre-
vious reports of a matching EST clone originating from this
cell line [13]. To monitor the expression of annexin A9 protein
in cultured cells we prepared polyclonal antibodies directed
against a synthetic peptide resembling a part of the N-termi-
nal domain of the protein. The sequence was chosen because
it showed a high degree of variation to N-terminal sequences
of other annexins and thus was likely to generate annexin A9-
speci¢c antibodies. The antibodies obtained recognized the
cognate, recombinantly expressed annexin A9 and not the
most closely related family members, annexins A1 and A2
(not shown). The immunoa⁄nity-puri¢ed anti-annexin A9
antibodies were then employed to stain Western blots of
whole cell lysates. As shown in Fig. 1B, a band corresponding
in size to that of recombinantly expressed annexin A9 was
stained in lysates from HepG2 hepatoma but not HeLa cells.
This signal was not observed with the pre-immune serum in-
dicating that it is due to speci¢c recognition of the endoge-
nous HepG2 annexin A9 protein (not shown). A limited ex-
pression pattern of the protein is in line with previous
observations on the limited abundance of annexin A9 sequen-
ces in EST libraries from di¡erent tissues or cells [13] and with
the limited presence of annexin A9 mRNAs in di¡erent mu-
rine organs [23]. The expression pro¢ling and an immunocy-
tochemical analysis of mouse embryos employing the anti-
body described here [23] reveals that the protein appears to
be restricted to certain types of tissues, in particular spleen
and liver. Such a speci¢c expression pattern contrasts with
that of most other annexins (for review see [2]) and argues
for a rather specialized function of annexin A9.
3.2. Expression of the annexin A9 protein in E. coli
To characterize the protein biochemically, we chose bacte-
rial expression of annexin A9 as full-length authentic protein.
Recombinant annexin proteins generated by bacterial expres-
sion systems in previous analyses have been shown to retain
their typical properties such as Ca2þ-regulated phospholipid
Fig. 1. Expression of endogenous annexin A9 in HepG2 cells.
A: RT-PCR performed with total RNA isolated from HepG2 and
HeLa cells. The size of the PCR product as deduced from the
cDNA sequence is estimated to be 1038 bp. B: Western blotting
with a⁄nity-puri¢ed anti-annexin A9 antibodies detects an immuno-
reactive band at the same apparent molecular mass as the bacterial-
ly expressed annexin A9 (lane 1) in total cell lysates from HepG2
(lane 2) but not HeLa cells (lane 3).
Fig. 2. Expression of human annexin A9 in E. coli. For comparison,
annexin A9 expressed in an eukaryotic in vitro translation reaction
is shown in lane 2. As a negative control the result of a TNT reac-
tion using an empty vector is depicted in lane 1. E. coli BL21(DE3)-
pLysS transformed with pET-23a(+)mod:/anxA9 was grown in LB
medium containing ampicillin and recombinant protein expression
was induced with 1 mM IPTG. Annexin A9 was then enriched as
described in Section 2 and protein samples of the di¡erent puri¢ca-
tion steps were analyzed by Western blotting using anti-annexin A9
antibodies. Lane 3, proteins from non-transformed bacteria; lanes 4
and 5, bacterial proteins prior to and following IPTG induction for
3 h, respectively; lane 6, soluble protein pool from the induced bac-
teria; lane 7, annexin A9 eluted from the DEAE column at 100 mM
NaCl.
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binding (see, for example, [24,25]). As shown in Fig. 2, IPTG
induced the transformed bacteria to produce annexin A9. To
verify the correct synthesis as full-length protein in E. coli, we
additionally used a system for eukaryotic translation in vitro.
Immunoreactive bands obtained by either bacterial expression
or eukaryotic in vitro translation migrated at the same appar-
ent molecular mass. Following cell lysis, the bacterially ex-
pressed protein was found in the soluble protein pool. Inter-
estingly, expression of annexin A9 was rather limited
compared to the expression of other annexins, e.g. annexin
A1, using the same expression system and mode of induction
(not shown).
3.3. Biochemical characteristics of recombinantly expressed
annexin A9 and expression of GFP-tagged annexin A9 in
HeLa cells
Annexin A9 present in the soluble bacterial lysate was en-
riched by ion exchange chromatography on DEAE cellulose.
Under the conditions chosen (pH 7.4) the protein eluted from
the column at approximately 100 mM NaCl (Fig. 2). This
correlates with the calculated isoelectric point of 5.29. Inspec-
tion of the eluted fraction revealed a number of additional
(bacterial) polypeptides with annexin A9 representing approx-
imately 10% of the total protein (not shown).
Annexin A9 present in the DEAE eluate was subjected to
Fig. 3. Ca2þ-dependent phospholipid binding of human annexin A9 (A) and S100A10 ligand binding blot (B). A: Annexin A9 present in the
DEAE eluate was mixed with phospholipid liposomes in the presence of either EGTA or increasing Ca2þ concentrations. Liposomes were pel-
leted, re-extracted with 100 mM EGTA and pelleted again. Supernatants of the ¢rst (SN Ca2þ) and second (SN EGTA) centrifugation and the
liposome pellets (LP) were analyzed by Western blotting using the anti-annexin A9 antibodies. In the case of annexin A9 bound in the presence
of 2.5 mM Ca2þ the liposome-bound material was ¢rst extracted in the bu¡er containing 100 mM EGTA (SN EGTA) and then subjected to
extraction with 100 mM EGTA and 0.2% Triton X-100. Following an additional centrifugation the detergent-extracted annexin A9 (SN Triton)
as well as the protein still bound to liposomes (LP) were visualized by Western blotting. Note the Ca2þ-dependent binding of annexin A9
which cannot be reversed by EGTA treatment. Only the inclusion of detergent leads to an extraction of some annexin A9 from the liposome
pellet. B: Annexin A9 present in the DEAE eluate (AnxA9), annexin A2 present in the annexin A2^S100A10 complex puri¢ed from intestinal
epithelial cells (AnxA2), a protein extract from non-transformed E. coli BL21 (BL21 wt) and an extract from transformed BL21 bacteria ex-
pressing annexin A9 (BL21 AnxA9) were subjected to SDS^PAGE, transferred to PVDF membrane and then incubated with puri¢ed S100A10
following a ligand blot protocol developed for visualizing the S100A10^annexin A2 interaction [31]. Bound S100A10 was detected with a specif-
ic monoclonal antibody. Subsequently the membrane was stripped and probed with anti-annexin A9 and anti-annexin A2 antibodies, respec-
tively. Note the binding of S100A10 to the immobilized annexin A2 which is not observed in the case of annexin A9.
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biochemical analyses. First, we performed liposome pelleting
experiments using brain extract liposomes containing approx-
imately 50% phosphatidylserine and increasing free Ca2þ con-
centrations. At Ca2þ concentrations of up to 1 mM, binding
of annexin A9 to the negatively charged liposomes was negli-
gible (Fig. 3A). This is in sharp contrast to the behavior of all
other annexins analyzed so far which show complete or al-
most complete binding to acidic liposomes at such Ca2þ levels
(see, for example, [26]), indicating that the amino acid sub-
stitutions in the cap residues of the type II Ca2þ binding sites
indeed have rendered these sites inactive in annexin A9. How-
ever, when Ca2þ was increased to 2.5 mM annexin A9 was co-
pelleted together with the liposomes. Most likely this low
a⁄nity binding is mediated through type III Ca2þ sites which
have also been found in all annexins crystallized in their Ca2þ-
bound form so far and are possibly unaltered in annexin A9.
Type III sites di¡er considerably from type II sites, both in
architecture and in a⁄nity for Ca2þ. They typically provide
carboxyl oxygens of an acidic residue and carbonyl oxygens of
a nearby site in the backbone for Ca2þ coordination and have
a Ca2þ a⁄nity which is at least an order of magnitude lower
than that of canonical type II sites [10,24,25]. Type III sites
have thus been considered irrelevant for intracellular activities
of annexins although they might participate in regulating
extracellular functions reported for some members of the an-
nexin family (for review see [2,27]). Interestingly and in con-
trast to other type II site annexin mutants engineered recom-
binantly [24,25], annexin A9 bound to liposomes at the
elevated Ca2þ levels could not be released by chelating Ca2þ
with EGTA. Only the inclusion of Triton X-100 in the EGTA
elution bu¡er resulted in a signi¢cant liberation of annexin A9
from the liposomes (Fig. 3A). These binding characteristics
suggest some conformational protein alteration in the annexin
A9^Ca2þ^liposome complex which probably slows down the
o¡ rate for Ca2þ or leads to an exposure of Ca2þ-insensitive
hydrophobic surfaces in the annexin A9 protein. Future ex-
periments have to address this question, e.g. by probing the
hydrophobic nature of the protein under di¡erent conditions
and elucidating the thermodynamics of ligand binding.
The liposome binding data indicate that annexin A9 is not
regulated by intracellular Ca2þ thus constituting a distinct and
so far non-described subgroup of the annexin family. Whether
or not the protein is capable of interacting with certain types
of cellular membranes in a manner not dependent on Ca2þ
remains to be determined. Such considerations are noteworthy
since the closest annexin A9 relative, annexin A2, can bind to
cholesterol-rich subdomains of cellular membranes in a Ca2þ-
independent manner [28]. Most likely, this interaction is medi-
ated through the unique N-terminal sequence which shows
some features reminiscent of the N-terminal domain of annex-
in A9 [29,30].
Another property uniquely displayed by the N-terminal do-
main of annexin A2 is its capability of interacting with the
S100 protein S100A10 [15]. This interaction, which can be
demonstrated by ligand overlay blotting [31], is mediated
through the N-terminal 12 residues of annexin A2 forming
an amphipathic K-helix. The corresponding sequence at the
N-terminal end of annexin A9 also shows a potential to
form an amphipathic K-helix and some residues participating
in annexin A2^S100A10 complex formation are conserved in
the N-terminal annexin A9 sequence. Therefore, we per-
formed S100A10 ligand overlays employing annexin A9 and
annexin A2 immobilized on PVDF membrane to elucidate
whether annexin A9 can also interact with S100A10. Fig. 3B
reveals that in contrast to annexin A2 the recombinantly ex-
pressed annexin A9 protein is not able to bind to S100A10.
While this argues against any annexin A9^S100A10 complex
formation it remains to be determined whether other protein
Fig. 4. Annexin A9 does not bind to F-actin. The ability of annexin A9 to bind or bundle F-actin was investigated in a co-sedimentation assay.
Annexin A9 present in the DEAE eluate was incubated with F-actin in the presence or absence of Ca2þ. F-actin bundling was detected by low
speed centrifugation (LSP) and F-actin binding by high speed centrifugation (HSP). Proteins left in the high speed centrifugation supernatant
(HSS) were precipitated with TCA. The di¡erent samples were analyzed by SDS^PAGE and then transferred to a PVDF membrane. After im-
munodetection with the polyclonal anti-annexin A9 antibody (upper panel), the membrane was stained with Coomassie to visualize F-actin
(lower panel).
Fig. 5. Intracellular distribution of annexin A9 in transfected HeLa
cells. HeLa cells were transfected with an expression construct en-
coding an annexin A9^GFP fusion protein (AnxA9) and the intra-
cellular distribution was visualized by recording the GFP signal. Ex-
pression constructs encoding GFP alone (GFP), annexin A1^GFP
(AnxA1) or annexin A2^GFP (AnxA2) were used as controls. Scale
bar: 10 Wm.
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ligands can interact with the unique N-terminal domain of
annexin A9.
Since annexin A2 is also an F-actin binding protein [20] and
since a sequence constituting a potential actin binding site is
conserved between annexins A2 and A9 [19], the recombi-
nantly expressed annexin A9 was also used in F-actin co-sed-
imentation experiments (Fig. 4). However, in contrast to an-
nexin A2, annexin A9 was unable to bind to actin ¢laments
even in the presence of high (4 mM) Ca2þ concentrations.
Thus the F-actin binding sequence mapped in annexin A2 is
per se not su⁄cient to mediate F-actin binding in an annexin
background. Additional parameters, most likely including in-
tact type II Ca2þ binding sites, are required.
The inability of annexin A9 to interact with F-actin is also
supported by our analysis of the intracellular distribution of a
C-terminally GFP-tagged annexin A9 in HeLa cells. Fig. 5
reveals that the fusion protein shows no indication of a colo-
calization with actin stress ¢bers or cortical actin ¢laments. It
is present throughout the cytoplasm as well as nucleoplasm.
Annexins A1 and A2 used as controls in these experiments are
found on endosomal vesicles and in the cytoplasm as well as
at the plasma membrane [11]. A nuclear export sequence
found in the N-terminal domain of annexin A2 has been
shown to confer nuclear exclusion for this annexin [32]. Inter-
estingly, a similar sequence involving regularly spaced leucine
residues is also present in annexin A9 but seems to be inef-
fective in this case.
In conclusion, our data con¢rm that annexin A9 is an atyp-
ical member of the annexin family, since it is not capable of
binding acidic phospholipids in the presence of submillimolar
Ca2þ concentrations. This suggests that the protein ful¢lls a
rather special function which due to its low abundance and
biochemical properties does not involve the providing of a
membrane sca¡old proposed for other annexins (for review
see [2]). High resolution structural studies have to reveal
whether annexin A9 shares a common structural fold with
other annexins with the core constituting an entity designed
to interact with negatively charged macromolecular surfaces.
Speci¢c functional insights are likely to be obtained by gene
disruption or silencing experiments as functional redundancy
is not expected in the case of annexin A9.
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